Evaluation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Intravenous Dose(s) and a Single Oral Dose of GW856553 in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 17 Jun 2017
At a glance
- Drugs Losmapimod (Primary) ; Losmapimod (Primary)
- Indications Atherosclerosis; Chronic obstructive pulmonary disease; Depression; Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 10 Jun 2017 Biomarkers information updated
- 19 May 2010 Actual number of patients changed from 4 to 16 as reported by ClinicalTrials.gov record.
- 04 May 2010 Actual patient number (4) added as reported by ClinicalTrials.gov.